Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
Lecia V. Sequist(Massachusetts General Hospital), Ji‐Youn Han(National Cancer Center), Myung‐Ju Ahn(Samsung Medical Center), Byoung Chul Cho(Yonsei University), Helena A. Yu(Memorial Sloan Kettering Cancer Center), Sang-We Kim(University of Ulsan), James Chih‐Hsin Yang(National Taiwan University Hospital), Jong Seok Lee(Seoul National University Bundang Hospital), Wu‐Chou Su(National Cheng Kung University Hospital), Dariusz M. Kowalski(Centrum Onkologii), Sergey Orlov, Mireille Cantarini(AstraZeneca (United Kingdom)), Remy B. Verheijen(AstraZeneca (United Kingdom)), Anders Mellemgaard(AstraZeneca (United Kingdom)), Lone H. Ottesen(AstraZeneca (United Kingdom)), Paul Frewer(AstraZeneca (United Kingdom)), Xiaoling Ou(AstraZeneca (United Kingdom)), Geoffrey R. Oxnard(Dana-Farber Cancer Institute)
Cited by 410Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis